Φορτώνει......
New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
Baricitinib is an innovative small-molecule drug that reversibly inhibits continuous activation of JAK/STAT pathway, thus reducing joint inflammation. The drug was approved for use as monotherapy or in combination with methotrexate (MTX) in the treatment of adults with moderately to severely active...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ther Clin Risk Manag |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6385775/ https://ncbi.nlm.nih.gov/pubmed/30858707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S192440 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|